In conclusion, our findings provide a novel signaling pathway, the VEGF-C/VEGFR3-KRAS/MAPK-YAP1/Slug axis, in skin cancer progression and a potential therapeutic strategy by treatment with an anti-VEGFR3 peptide. The gene discussed is KRAS; the disease is skin cancer.